Submit an abstract for the 56th ASH Annual Meeting. The deadline to submit abstracts is August 5, 2014, 11:59 p.m. (PDT).
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research
ASH is committed to helping practicing hematologists provide quality care to patients, continue their professional development, and enhance their knowledge and expertise.
Resources to help practitioners improve the quality of hematologic care provided to patients
Resources to support hematologists with both continuing medical education and maintaining board certification
Newly approved therapies and updates on shortages of hematologic drugs
Service that provides advice on clinical questions in one to two days
Information on federal programs and policies affecting clinical practice
Dr. Deepa Suryanarayan and Dr. David Garcia discuss their approach to a patient with laboratory evidence of anti-phospholipid antibodies who is pregnant or considering pregnancy.
Dr. Janet Abrahm discusses her approach to the management of chemotherapy-induced peripheral neuropathy.
Dr. Adam Cuker discusses the
use of platelet aggregation studies
in the evaluation of patients with a
suspected bleeding disorder.
Dr. Karen Quillen reviews her approach to the diagnosis and management of platelet alloimmunization.
On July 23, 2014, the U.S. Food and Drug Administration (FDA) approved idelalisib (Zydelig® tablets, Gilead Sciences, Inc.) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
On April 28, 2014, the U. S. Food and Drug Administration approved an oral suspension of mercaptopurine (Purixan ®, NOVA Laboratories Limited). Mercaptopurine is a 20 mg/ml oral suspension. Purixan is indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination regimen.
On April 17, 2014, the U. S. Food and Drug Administration approved ofatumumab (Arzerra Injection, for intravenous infusion; GlaxoSmithKline) in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.
FDA Approves Ibrutinib to Treat Chronic Lymphocytic Leukemia
In collaboration with the Food and Drug Administration (FDA), and as a service to our members, ASH provides information about newly approved therapies and other important FDA actions (e.g., updated safety information, ne
Earlier today, the U.S. House of Representatives passed a bill that would avert the more than 20% cut to Medicare physician payment mandated by the Sustainable Growth Rate (SGR) formula on April 1, 2014.
On February 6, 2014 the leadership of the House Ways and Means and Energy and Commerce Committees and the Senate Finance Committee released a bi-partisan and bicameral bill to repeal the Sustainable Growth Rate (SGR) formula that has driven annual reductions in Medicare payment for physician services.
Over the past two years, shortages of drugs and biologics used to treat patients with hematologic diseases, including leukemia and lymphoma, became critical and life-threatening.
Over the past year, ASH has been very active on physician payment issues.
Explore the ASH Academy, the eLearning platform for hematologists.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology